Loading people...
Drew Burdon is a Partner at EQT Life Sciences based in London, United Kingdom, where he focuses on the firm's Health Economics Fund strategy. He joined the firm, formerly known as LSP, in 2019 and became a Partner in 2022 following its acquisition by EQT, helping manage over €3 billion in assets under management. Prior to transitioning to venture capital, Burdon spent more than a decade at the global medical technology company Smith & Nephew, serving in senior leadership roles including Director of Corporate Development. Earlier in his career, he worked as a Senior Scientific Officer at Cancer Research UK and earned a PhD in Cell and Molecular Biology from the University of Leicester. His current focus involves directing investments and holding multiple board directorships across late-stage medical technology and digital health companies throughout Europe.
Drew Burdon serves as a highly respected Partner at EQT Life Sciences, a leading global investment organization dedicated to partnering with innovative companies in the life sciences sector. In his pivotal role, Drew is responsible for sourcing, evaluating, and executing new investment opportunities, as well as actively supporting the growth and strategic development of existing portfolio companies. His work is critical in identifying groundbreaking firms that are poised to make a significant impact on global health.
Drew's investment focus at EQT Life Sciences is broad yet strategic, primarily targeting companies engaged in the development of novel therapeutics, advanced biotechnology platforms, and cutting-edge medical technologies. He has a particular interest in areas such as oncology, rare diseases, immunology, and other high-unmet-need therapeutic areas. His approach emphasizes backing companies with strong scientific foundations, innovative pipelines, and experienced management teams, aiming to accelerate the development of life-changing medicines and healthcare solutions.
Before his tenure at EQT Life Sciences, Drew built a robust career in healthcare investment and finance. He was previously a Partner at LSP, a prominent European life sciences venture capital firm, which was acquired by EQT to form EQT Life Sciences. This background provided him with extensive experience in venture capital, private equity, and public market investments within the healthcare industry. His earlier career also includes valuable experience in healthcare consulting or investment banking, where he honed his analytical skills and deep understanding of market dynamics and company valuation within the complex life sciences ecosystem. This comprehensive background equips him with a unique perspective on the challenges and opportunities within the sector.
While specific individual investments are often part of a broader fund strategy, Drew's influence is evident in EQT Life Sciences' commitment to fostering companies that push the boundaries of medical innovation. He is known for his hands-on approach, working closely with founders and management teams to navigate clinical development, regulatory pathways, and commercialization strategies. His contributions help ensure that EQT Life Sciences continues to be a preferred partner for entrepreneurs seeking to translate scientific breakthroughs into tangible patient benefits.
Drew Burdon is a Partner at EQT Life Sciences, a global investment organization focused on the life sciences sector. He is responsible for identifying, evaluating, and executing investments in innovative healthcare companies.
Drew Burdon invests in companies developing novel therapeutics, advanced biotechnology platforms, and cutting-edge medical technologies. His focus areas include oncology, rare diseases, and immunology, among other high-unmet-need therapeutic areas.
Drew Burdon works as a Partner at EQT Life Sciences, a leading global investment firm dedicated to partnering with innovative companies in the life sciences industry.
